Antiviral Drug Resistance Market Growth Drivers and Forecast by 2031

The antiviral drug resistance market size is projected to reach US$ 6.35 billion by 2031 from US$ 3.44 billion in 2023. The market is expected to register a CAGR of 7.9% during 2023–2031. Rising in incidences of hepatic diseases, the prevalence of HIV and AIDS, and demand for high-quality products in emerging nations are likely to remain key trends in the market.

Antiviral Drug Resistance Market Analysis

The prevalence of HIV/AIDS has increased in recent years worldwide. Acquired immunodeficiency syndrome (AIDS) is a chronic, potentially life-threatening condition which is caused by a human immunodeficiency virus (HIV). The virus is responsible for damaging the immune system, where HIV interferes with the body's ability to fight the organisms that cause disease. When HIV enters the body, it develops a flu-like illness within a month. This illness is known as primary or acute HIV infection that may last for a few weeks. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), in 2022, approx. 39 million people were living worldwide with HIV/AIDS. A massive majority of people living with HIV are in low- and middle-income countries. For instance, according to the India HIV Estimation 2017 report (National Informatics Centre), in India, the prevalence of HIV is estimated at 0.22% (0.16%–0.30%). Moreover, an adult HIV prevalence is estimated at 0.25% (0.18%-0.34%) among males and at 0.19% (0.14-0.25) among Females. Hence, the cases of viral infections in the country are anticipated to drive the demand for the antiviral drug resistance market during the forecast period

Antiviral Drug Resistance Market Overview

Rise in the incidences of hepatitis diseases and increasing prevalence of HIV/AIDS are boosting the growth of the market over the years. Also, the increase in the emerging market is likely to have a positive impact on the demand for the market during the forecast period. However, the growth of the market is restrained by a factor such as alternative approaches. The prevalence of HIV in the US has increased during recent years. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), almost 32,100 Americans were newly infected with HIV during 2021. Hence, the factors as mentioned above are anticipated to fuel the growth of North America antiviral drug resistance market during the forecast period.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Antiviral Drug Resistance Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Antiviral Drug Resistance Market Drivers and Opportunities

Rising Incidences of Hepatic Diseases to Favor Market

Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems. The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer. Hepatitis can be categorized as hepatitis A, B, C, D, and E that spread through different causes. According to the WHO (World Health Organization), the prevalence of Hepatitis B is the highest in the African and Western Pacific Region, where 6.1% and 6.2% of the adult population is infected respectively.

Increasing Healthcare Expenditures in Emerging Markets

The increasing healthcare expenditure in emerging economies such as Asia Pacific and South and Central America are enabling researchers to develop treatment options for a wide range of viral diseases by utilizing advanced techniques such as PCR (Polymerase Chain Reaction), next-generation sequencing, and others. Several organizations such as, National Cancer Institute (NCI) funded for HIV and AIDS Malignancies Research to study about how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer. China, Japan, Brazil and other emerging nations are spending heavily on healthcare expenditure to establish their presence in the market as well as to ensure the appropriate use of instruments and reagents used in hospitals and research institutes, pathological labs and other destinations in their respective countries.

Antiviral Drug Resistance Market Report Segmentation Analysis

Key segments that contributed to the derivation of the antiviral drug resistance market analysis are type, disease indication, technology, and end users.

• Based on type, the antiviral drug resistance market is divided into into kits and reagents and instruments. The kits and reagents segment held the largest share of the market in 2023.
• By disease indication, the market is segmented into HIV, hepatitis and Cytomegalovirus (CMV). The HIV segment held the largest share of the market in 2023.
• In terms of technology, the market is segmented into immunodiagnostics, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. The immunodiagnostics segment held a significant share of the market in 2023.
• Based on end users, the antiviral drug resistance market is divided into into hospitals and clinics, pathology or diagnostic laboratories and research institutes. The hospitals and clinics segment held the largest share of the market in 2023.

Antiviral Drug Resistance Market Share Analysis by Geography

The geographic scope of the antiviral drug resistance market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America has largest market share of the high-flow nasal cannula market, by geography. The demand for the market is anticipated to grow at a substantial rate during the forecast period owing to various factors such as prevalence of viral infections such as HIV and hepatitis, presence of national programmes and funding by government bodies. The prevalence of HIV in the US has increased during recent years. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), almost 32,100 Americans were newly infected with HIV during 2021. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.

Antiviral Drug Resistance Market Regional Insights

The regional trends and factors influencing the Antiviral Drug Resistance Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Antiviral Drug Resistance Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Antiviral Drug Resistance Market Report Scope

Antiviral Drug Resistance Market Players Density: Understanding Its Impact on Business Dynamics

The Antiviral Drug Resistance Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Antiviral Drug Resistance Market are:

1. AccuBioTech Co., Ltd.;
2. ACON Laboratories, Inc.;
3. Siemens AG;
4. BioMérieux SA;
5. Bio-Rad Laboratories, Inc.;
6. Danaher;

Disclaimer: The companies listed above are not ranked in any particular order.

Antiviral Drug Resistance Market News and Recent Developments

The antiviral drug resistance market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the antiviral drug resistance market are listed below:

• – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical study, is now progressing into Phase 2 clinical studies for the prevention and treatment of dengue. (Source: Johnson & Johnson, Press Release, March 2023)
• Cipla Limited announced that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu®. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease. (Source: Cipla, Press Release, May 2021)

Antiviral Drug Resistance Market Report Coverage and Deliverables

The “Antiviral Drug Resistance Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Antiviral Drug Resistance market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Antiviral Drug Resistance market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Antiviral Drug Resistance market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Antiviral Drug Resistance market
• Detailed company profiles